ABSTRACT
CovidSIMVL, an agent-based contagion-based viral transmission simulation tool, was employed to simulate the effects of viral agents of differing levels of infectivity. The constructs “Velocity” and “Increase in Velocity” were operationalized in terms of rates of transmission events over successive iterations (generations) in a set of CovidSIMVL trials. Treating 40-70% increase in velocity as a target, based on reports in the literature for the UK variant (VUI 202012/01), the series of trials reported in the paper demonstrate the calibration of CovidSIMVL parameters to produce increases in transmission rates of 40-70% above a baseline value. A series of follow-up studies is proposed to evaluate three different possible explanations for reported increases in SARS-Cov2-2 infections that are being attributed to spread of the UK and other variants: (a) simulations where the inherent characteristics of the virus (infectivity) are varied (genomic studies); (b) simulations where the behaviour of agents is varied (e.g., movement within and between spaces) while inherent characteristics of the virus are held constant (behavioural studies); and (c) simulations where both inherent properties of the virus and the behaviour of agents are varying to “tease out” the interaction between biologically-based contributions to increased case counts, and contextual/behavioural contributions (epigenetic studies).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/ecsendmail/MultiverseContagion
Funding Statement
The work is funded by the Michael Smith Foundation and the Victoria Hospitals Foundation. Dr. Moselle's time is covered by Island Health (Vancouver Island Health Authority) as the products are generated as a part of his organizationally mandated job responsibilities.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Work is funded by Michael Smith Foundation and Victoria Hospitals foundation in BC and has ethics approval from harmonized ethics review in BC (RISe)which is hosted by University of British Columbia. The work also has REB ethics approval and operational approval from Island Health (Vancouver Island Health Authority).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The work reported in the paper consists of simulated clinical trials, using CovidSIMVL - an agent-based modeling tool, available at github.com/ecsendmail/ MultiverseContagion. The parameters used to generate the simulations are set out in the paper.